Beyond novel MDM2-targeting compounds, several existing clinically approved drugs also exhibit secondary activities against MDM2, such as albendazole and fenbendazole, which upregulate p53 and its downstream effector, p21, by significantly decreasing the expression of MDM2 and MDMX in melanoma and breast cancer cell lines 76. Here, MDM2 is linked to melanoma.